X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs FRESENIUS KABI ONCO. - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA FRESENIUS KABI ONCO. ABBOTT INDIA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 42.0 22.1 189.7% View Chart
P/BV x 10.5 3.1 336.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs6,015176 3,417.6%   
Low Rs3,70779 4,722.3%   
Sales per share (Unadj.) Rs1,236.937.7 3,282.2%  
Earnings per share (Unadj.) Rs122.25.1 2,398.9%  
Cash flow per share (Unadj.) Rs129.06.7 1,918.4%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.242.5 1,225.2%  
Shares outstanding (eoy) m21.25158.23 13.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.93.4 116.4%   
Avg P/E ratio x39.825.0 159.2%  
P/CF ratio (eoy) x37.718.9 199.1%  
Price / Book Value ratio x9.33.0 311.8%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,29620,135 513.0%   
No. of employees `0003.01.2 256.6%   
Total wages/salary Rs m3,370703 479.2%   
Avg. sales/employee Rs Th8,891.85,176.2 171.8%   
Avg. wages/employee Rs Th1,140.0610.4 186.8%   
Avg. net profit/employee Rs Th878.3699.6 125.6%   
INCOME DATA
Net Sales Rs m26,2845,963 440.8%  
Other income Rs m50418 2,802.2%   
Total revenues Rs m26,7895,981 447.9%   
Gross profit Rs m3,6651,430 256.3%  
Depreciation Rs m144258 56.0%   
Interest Rs m8-26 -31.2%   
Profit before tax Rs m4,0171,216 330.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,421342 415.3%   
Profit after tax Rs m2,596806 322.2%  
Gross profit margin %13.924.0 58.1%  
Effective tax rate %35.428.1 125.7%   
Net profit margin %9.913.5 73.1%  
BALANCE SHEET DATA
Current assets Rs m14,4465,102 283.2%   
Current liabilities Rs m4,7252,385 198.1%   
Net working cap to sales %37.045.6 81.2%  
Current ratio x3.12.1 143.0%  
Inventory Days Days51150 34.3%  
Debtors Days Days20113 17.3%  
Net fixed assets Rs m1,1135,148 21.6%   
Share capital Rs m213158 134.3%   
"Free" reserves Rs m10,8086,556 164.9%   
Net worth Rs m11,0766,732 164.5%   
Long term debt Rs m0952 0.0%   
Total assets Rs m16,24110,388 156.3%  
Interest coverage x497.0-45.8 -1,085.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.60.6 281.9%   
Return on assets %16.07.5 213.6%  
Return on equity %23.412.0 195.8%  
Return on capital %36.314.6 248.9%  
Exports to sales %0.674.5 0.8%   
Imports to sales %12.624.8 51.0%   
Exports (fob) Rs m1624,441 3.6%   
Imports (cif) Rs m3,3221,477 224.9%   
Fx inflow Rs m2685,298 5.1%   
Fx outflow Rs m3,9271,772 221.6%   
Net fx Rs m-3,6593,525 -103.8%   
CASH FLOW
From Operations Rs m2,5141,274 197.3%  
From Investments Rs m-800-1,204 66.4%  
From Financial Activity Rs m-803-196 409.4%  
Net Cashflow Rs m912-126 -722.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 9.6 1.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 42,599 42.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 19, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS